Get the Stockscreener App
48.66
1.99%
0.95
Pre-market:
48.29
-0.37
-0.76%
Harrow Inc stock is traded at $48.66, with a volume of 451.18K.
It is up +1.99% in the last 24 hours and up +4.02% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$47.71
Open:
$48.01
24h Volume:
451.18K
Relative Volume:
0.74
Market Cap:
$1.80B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-50.69
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
+3.09%
1M Performance:
+4.02%
6M Performance:
+44.22%
1Y Performance:
+53.26%
1-Day Range:
$46.21
$49.45
1-Week Range:
$45.40
$49.45
52-Week Range:
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
48.66 | 1.77B | 154.15M | -33.58M | -20.74M | -0.96 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Will Harrow Inc. stock attract more institutional investorsWeekly Trade Report & Weekly High Return Stock Forecasts - mfd.ru
Is Harrow’s (HROW) Reaffirmed 2025 Guidance Quietly Redefining Its Ophthalmic Growth Strategy? - simplywall.st
Harrow Refocuses After ImprimisRx Exit As New CCO Takes Charge - Sahm
A Look At Harrow’s (HROW) Valuation As 2025 Guidance Is Reaffirmed And Regulatory Issues Clear - Yahoo Finance
New York State Common Retirement Fund Raises Stock Position in Harrow, Inc. $HROW - MarketBeat
B.Riley reiterates Buy rating on Harrow Health stock amid VEVYE growth - Investing.com
Harrow (NASDAQ:HROW) Downgraded by Zacks Research to "Hold" - MarketBeat
Growth Recap: Should I hold or sell Harrow Inc now2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - baoquankhu1.vn
Harrow Reaffirms FY2025 Revenue Growth Range Of 35% To 40%; Expands Sales Force - Nasdaq
Harrow Stock (+9.7%): Commercial Expansion Ignites Institutional Buying - Trefis
Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? - Nasdaq
Rival quits California market; OSRX steps in to keep eye meds flowing - stocktitan.net
How Harrow Health Inc. (HROW) Affects Rotational Strategy Timing - Stock Traders Daily
Harrow on track to double sales force, expand product reach By Investing.com - Investing.com Nigeria
OSRX Continues Support in California Market After Competitor Exit - Intellectia AI
Harrow (NASDAQ:HROW) Shares Gap UpShould You Buy? - MarketBeat
Harrow on track to double sales force, expand product reach - Investing.com
(HROW) Harrow Expects 2025 Revenue Range $270M$280M, vs. FactSet Est of $273.4M - marketscreener.com
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth - marketscreener.com
Is Harrow Inc. attractive for institutional investors2025 Winners & Losers & Verified Momentum Stock Alerts - Mfd.ru
Harrow Becomes Oversold (HROW) - Nasdaq
Can Harrow Inc. be recession proofJuly 2025 Rallies & Daily Volume Surge Signals - mfd.ru
Risk Report: Is PMTV stock showing strong momentum2025 Price Targets & Low Volatility Stock Recommendations - baoquankhu1.vn
109,421 Shares in Harrow, Inc. $HROW Acquired by Blackhawk Capital Partners LLC - MarketBeat
Harrow, Inc. (NASDAQ:HROW) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update (NASDAQ:HROW) - Seeking Alpha
Harrow (NASDAQ:HROW) Shares Down 4.4%Time to Sell? - MarketBeat
Market Trends: Can Harrow Inc expand into new marketsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Pharma News: Can Harrow Inc. be recession proofTrade Risk Assessment & Weekly High Return Stock Forecasts - baoquankhu1.vn
Investment Recap: Can OptimizeRx Corporation weather a recessionQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) - Yahoo Finance
Assessing Harrow (HROW) Valuation After Its Shift To An Integrated U.S. Eye Care Pharma Platform - Sahm
LJI Wealth Management LLC Makes New Investment in Harrow, Inc. $HROW - MarketBeat
Opaleye management sells $711,814 worth of Harrow shares - MSN
Harrow announces leadership changes, Andrew Boll to serve as President and CFO - MSN
Harrow, Inc. (NASDAQ:HROW) Could Be Less Than A Year Away From Profitability - 富途资讯
Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength - sharewise.com
Harrow, Inc. (HROW): A Bull Case Theory - Finviz
Zacks Research Upgrades Harrow (NASDAQ:HROW) to "Strong-Buy" - MarketBeat
Gap Down: Can Harrow Inc maintain sales growthBull Run & Safe Capital Allocation Plans - baoquankhu1.vn
Panic Selling: What are the future prospects of Harrow IncTrade Exit Summary & Real-Time Volume Analysis - baoquankhu1.vn
Harrow: Flirting With Missing 2025 Revised Guidance (NASDAQ:HROW) - Seeking Alpha
Value Recap: Will Harrow Inc benefit from geopolitical trendsWeekly Trend Summary & Weekly Momentum Stock Picks - baoquankhu1.vn
Responsive Playbooks and the HROW Inflection - Stock Traders Daily
Institution Moves: Is Harrow Inc stock attractive for ETFsTrade Analysis Summary & Low Drawdown Investment Strategies - moha.gov.vn
Harrow Stock (-8.3%): Major Holder Sale Near Highs Sparks Distribution - Trefis
Evaluating Harrow (HROW) After Recent Share Price Swings And Long Term Return Strength - simplywall.st
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):